Sudan Ebolavirus – Experts deliberations. Candidate treatments prioritization and trial design discussions
October & November 2022
15 November 2022
| Meeting report
Overview
Given that there is no known effective treatment for Sudan ebolavirus (SUDV) and considering the current SUDV outbreak in Uganda, several meetings were held throughout October and November 2022 to plan and implement a clinical trial protocol for candidate therapeutics against Sudan ebolavirus disease.
These expert consultations included clinicians and researchers from the Ugandan Ministry of Health, organizations supporting Ebola treatment centers (ETCs), filovirus experts, experts in the field of randomized controlled trials (RCTs) for evaluation of investigational therapeutics (clinical experts, trialists, and statisticians) and regulatory experts.
The objectives of the consultations were:
- To review and critically appraise the existing evidence regarding different investigational therapeutic agents and reach a consensus on prioritization of therapeutics for a clinical trial.
- To discuss the design options and reach consensus on the design and implementation of a clinical trial.
- To discuss a proposed protocol based on the prioritized trial design options.
The expert consultation participants also considered designs with the ability to cumulatively collect evidence across multiple outbreaks if needed.
WHO Team
R&D Blue Print (RDB)